Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial

被引：7
|
作者：
Fjorden, Karin [1 ]
Ekberg, Sara [2 ]
Kuric, Nevzeta [3 ]
Smedby, Karin E. [4 ,5 ]
Lagerlof, Ingemar [6 ]
Larsen, Thomas S. [7 ]
Jorgensen, Judit M. [8 ]
de Nully Brown, Peter [9 ]
Jerkeman, Mats [1 ]
机构：
[1] Lund Univ, Skane Univ Hosp, Dept Oncol, Lund, Sweden
[2] Karolinska Inst, Dept Med Solna, Div Clin Epidemiol, Stockholm, Sweden
[3] Halmstad Cty Hosp, Dept Hematol, Halmstad, Sweden
[4] Karolinska Inst, Div Hematol, Dept Med Solna, Stockholm, Sweden
[5] Karolinska Univ Hosp, Stockholm, Sweden
[6] Linkoping Univ, Dept Med & Hlth Sci, Div Drug Res, Linkoping, Sweden
[7] Odense Univ Hosp, Dept Haematol, Odense, Denmark
[8] Aarhus Univ Hosp, Dept Hematol, Aarhus, Denmark
[9] Copenhagen Univ Hosp, Rigshosp, Dept Hematol, Copenhagen, Denmark
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 196卷 / 02期
关键词：
Idelalisib; relapsed; refractory DLBCL; transformed lymphoma; IBRUTINIB;
D O I：
10.1111/bjh.17792
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：437 / 440
页数：4
相关论文
共 50 条
  • [1] Idelalisib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: First Results from the Nordic Lymphoma Group NLG-LBC-07 (ILIAD) Phase II Trial
    Fjorden, Karin
    Ekberg, Sara
    Kuric, Nevzeta
    Smedby, Karin Ekstroem
    Lagerlof, Ingemar
    Larsen, Thomas S.
    Jorgensen, Judit M.
    Brown, Peter de Nully
    Jerkeman, Mats
    BLOOD, 2020, 136
  • [2] A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma
    Collins, Graham P.
    Eyre, Toby A.
    Linton, Kim M.
    Radford, John
    Vallance, Grant D.
    Soilleux, Elizabeth
    Hatton, Chris
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (06) : 886 - 890
  • [3] Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Friedberg, Jonathan W.
    HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM, 2011, : 498 - 505
  • [4] Phase I/II Clinical Trial of Ibrutinib and Buparlisib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, and Follicular Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (08) : 17 - 18
  • [5] Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma.
    Batlevi, Connie Lee
    De Frank, Stephanie
    Stewart, Caitlin
    Hamlin, Paul A.
    Matasar, Matthew J.
    Gerecitano, John F.
    Moskowitz, Alison J.
    Hamilton, Audrey M.
    Zelenetz, Andrew David
    Drullinsky, Pamela
    Straus, David J.
    Kumar, Anita
    Moskowitz, Craig H.
    Dicostanzo, Joanna
    Callan, Devin
    Tsui, Dana
    Rademaker, Jurgen
    Schoder, Heiko
    Ni, Ai
    Younes, Anas
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma
    Lu, Q.
    Huang, H.
    Tang, S.
    Wang, Y.
    Yang, D-H
    DRUGS OF TODAY, 2021, 57 (09) : 571 - 580
  • [7] Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Dickinson, Michael J.
    Carlo-Stella, Carmelo
    Morschhauser, Franck
    Bachy, Emmanuel
    Corradini, Paolo
    Iacoboni, Gloria
    Khan, Cyrus
    Wrobel, Tomasz
    Offner, Fritz
    Wu, Shang-Ju
    Cartron, Guillaume
    Hertzberg, Mark
    Sureda, Anna
    Perez-Callejo, David
    Lundberg, Linda
    Relf, James
    Dixon, Mark
    Clark, Emma
    Humphrey, Kathryn
    Hutchings, Martin
    Trney, Marek
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (24): : 2220 - 2231
  • [8] Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma
    Herrera, Alex F.
    Chen, Lu
    Popplewell, Leslie L.
    Budde, Lihua E.
    Mei, Matthew
    Armenian, Saro H.
    Darrah, Justin
    Nikolaenko, Liana
    Chen, Robert W.
    Peters, Lacolle
    Kennedy, Neena
    Rosen, Steven
    Forman, Stephen J.
    Kwak, Larry W.
    BLOOD, 2019, 134
  • [9] A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
    Flinn, Ian W.
    Bartlett, Nancy L.
    Blum, Kristie A.
    Ardeshna, Kirit M.
    LaCasce, Ann S.
    Flowers, Christopher R.
    Shustov, Andrei R.
    Thress, Kenneth S.
    Mitchell, Patrick
    Zheng, Fred
    Skolnik, Jeffrey M.
    Friedberg, Jonathan W.
    EUROPEAN JOURNAL OF CANCER, 2016, 54 : 11 - 17
  • [10] A Phase II Trial of Alemtuzumab (Campath) with DA-EPOCH-R in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
    Grant, Cliona
    Dunleavy, Kieron
    Hessler, Julieanne
    Steinberg, Seth M.
    Pittaluga, Stefania
    Jaffe, Elaine S.
    Wilson, Wyndham H.
    BLOOD, 2012, 120 (21)
12345